Harpago

Over 70% of small-molecule therapeutics emerging from today's discovery pipelines are too poorly water-soluble to enable adequate bioavailability after oral intake. This solubility problem greatly hinders drug development and ultimately prevents patients from accessing potentially life-saving treatments.

Harpago is dedicated to defeating low solubility through rigorous formulation design and development.